The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 531 participants.

Also called NCT02059187

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 531 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02059187
  • EudraCT 2012-003478-19
Other papers using this trial's data
  • Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29761615

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02059187. Randomized; no masking; primary purpose treatment. Start 2014-02-11 (actual); primary completion 2015-03-11 (actual). Results posted on 2017-03-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
MK-1293
Intervention (Drug)
Lantus™
Intervention (Drug)
Prandial insulin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct02059187
Content hash
44edb42d512a2ef3ac09ec9582091a1a88db0e9293769a99787cc2ea7e688fba